SCHEMBL16439749

SCHEMBL16439749

CC(C)(C)[Si](C)(C)OC[C@H]1CNCC2(CC2)N1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.34
THRB P10828 1/20 0.34
ADRA2A P08913 2/20 0.33
SIGMAR1 Q99720 2/20 0.33
HTR2A P28223 1/20 0.33
OPRK1 P41145 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
HIF1A Q16665 1/20 0.31
KCNH2 Q12809 1/20 0.30
DUT P33316 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16430424 0.99 OPRK1 (0.34) TOP2ATHRBADRA2ASIGMAR1HTR2A
Hydrochloric Acid SCHEMBL16430426 0.99 OPRK1 (0.34) TOP2ATHRBADRA2ASIGMAR1HTR2A
SCHEMBL17979207 0.84 TOP2A (0.36) TOP2ATHRBADRA2ASIGMAR1HTR2A
SCHEMBL22443406 0.84 TOP2A (0.36) TOP2ATHRBADRA2ASIGMAR1HTR2A
SCHEMBL18018313 0.84 TOP2A (0.36) TOP2ATHRBADRA2ASIGMAR1HTR2A
SCHEMBL16430298 0.81 ADRA2A (0.35) TOP2ATHRBADRA2ASIGMAR1HTR2A
SCHEMBL16430295 0.81 ADRA2A (0.35) TOP2ATHRBADRA2ASIGMAR1HTR2A
SCHEMBL2492327 0.77 TOP2A (0.33) TOP2ATHRBADRA2ASIGMAR1CYP2C19
SCHEMBL22443700 0.77 TOP2A (0.36) TOP2ATHRBADRA2ASIGMAR1HTR2A
SCHEMBL22443698 0.77 TOP2A (0.36) TOP2ATHRBADRA2ASIGMAR1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9840478-B2 Piperazine derivatives as HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-12-12 US disclosed
US-9840478-B2 Piperazine derivatives as HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-12-12 US disclosed
US-20160159752-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-09 US disclosed
US-20160159752-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-09 US disclosed
WO-2015013835-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-02-05 WO disclosed
WO-2015017393-A2 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159752-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS PREP, CTSZ, PEPD TOP2A 2002/4885THRB 4757/4885ADRA2A 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.